Metastatic colorectal cancer: Current treatment and future options for improved survivalMedical approach – present status
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Metastatic colorectal cancer: Current treatment and future options for improved survivalMedical approach – present status
Authors
Keywords
-
Journal
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
Volume 47, Issue 3, Pages 296-314
Publisher
Informa UK Limited
Online
2012-01-16
DOI
10.3109/00365521.2012.640828
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (mCRC): Analysis of patients with KRAS-mutated tumors in the randomized German AIO study KRK-0306.
- (2017) S. Stintzing et al. JOURNAL OF CLINICAL ONCOLOGY
- The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation
- (2014) D Hind et al. HEALTH TECHNOLOGY ASSESSMENT
- The Impact of Chemotherapy on Overall Survival and Quality of Life of Patients with Metastatic Colorectal Cancer: A Review of Phase III Trials
- (2014) C. Funaioli et al. JOURNAL OF CHEMOTHERAPY
- Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer
- (2011) Finn Ole Larsen et al. ACTA ONCOLOGICA
- A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: A Hellenic Cooperative Oncology Group study
- (2011) Christos A Papadimitriou et al. BMC Medicine
- Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy
- (2011) P Österlund et al. BRITISH JOURNAL OF CANCER
- XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results
- (2011) J Cassidy et al. BRITISH JOURNAL OF CANCER
- Irinotecan-Cetuximab-Bevacizumab as a Salvage Treatment in Heavily Pretreated Metastatic Colorectal Cancer Patients: A Retrospective Observational Study
- (2011) J. Feliu Batlle et al. CHEMOTHERAPY
- Improvements in population-based survival of patients presenting with metastatic rectal cancer in the south of the Netherlands, 1992–2008
- (2011) V. E. P. P. Lemmens et al. CLINICAL & EXPERIMENTAL METASTASIS
- Predictive and Prognostic Biomarkers for Targeted Therapy in Metastatic Colorectal Cancer
- (2011) Uzma Asghar et al. Clinical Colorectal Cancer
- Differences according to educational level in the management and survival of colorectal cancer in Sweden
- (2011) Nina Cavalli-Björkman et al. EUROPEAN JOURNAL OF CANCER
- Impact of Young Age on Treatment Efficacy and Safety in Advanced Colorectal Cancer: A Pooled Analysis of Patients From Nine First-Line Phase III Chemotherapy Trials
- (2011) Charles D. Blanke et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK-0104—A Randomized Trial of the German AIO CRC Study Group
- (2011) Nicolas Moosmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial
- (2011) Matthew T Seymour et al. LANCET
- Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial
- (2010) R. Labianca et al. ANNALS OF ONCOLOGY
- Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis
- (2010) R Zarate et al. BRITISH JOURNAL OF CANCER
- Towards a renaissance of subgross breast morphology
- (2010) Tibor Tot EUROPEAN JOURNAL OF CANCER
- Colorectal cancer molecular biology moves into clinical practice
- (2010) C. C. Pritchard et al. GUT
- Chemotherapy-Free Intervals for Patients With Metastatic Colorectal Cancer Remain an Option
- (2010) Tim Maughan et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
- (2010) Marc Peeters et al. JOURNAL OF CLINICAL ONCOLOGY
- Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study
- (2010) Niall C. Tebbutt et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08
- (2010) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis
- (2010) G. Masi et al. JNCI-Journal of the National Cancer Institute
- Treatment of Colorectal Cancer with and without Bevacizumab: A Phase III Study
- (2010) G.P. Stathopoulos et al. ONCOLOGY
- Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial
- (2010) Janja Ocvirk WORLD JOURNAL OF GASTROENTEROLOGY
- Systemic Therapy for Metastatic Colorectal Cancer: Patterns of Chemotherapy and Biologic Therapy Use in US Medical Oncology Practice
- (2010) Gregory P. Hess et al. Journal of Oncology Practice
- A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer
- (2009) B. Glimelius et al. ANNALS OF ONCOLOGY
- Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel
- (2009) B. Nordlinger et al. ANNALS OF ONCOLOGY
- Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study
- (2009) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer
- (2009) E Vasile et al. BRITISH JOURNAL OF CANCER
- Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients
- (2009) Halfdan Sorbye et al. CANCER
- Retrospective Analysis of S-1 Monotherapy in Patients with Metastatic Colorectal Cancer After Failure to Fluoropyrimidine and Irinotecan or to Fluoropyrimidine, Irinotecan and Oxaliplatin
- (2009) H. Yasui et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Stop and Go: Yes or No?
- (2009) Howard S. Hochster JOURNAL OF CLINICAL ONCOLOGY
- KRASandBRAFMutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial
- (2009) Susan D. Richman et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Noninferiority Trial Comparing Irinotecan With Oxaliplatin, Fluorouracil, and Leucovorin in Patients With Advanced Colorectal Carcinoma Previously Treated With Fluorouracil: N9841
- (2009) George P. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study
- (2009) Benoist Chibaudel et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care
- (2009) Neal J. Meropol et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
- (2009) Thierry André et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
- (2009) Gunnar Folprecht et al. LANCET ONCOLOGY
- Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
- (2009) Jolien Tol et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study
- (2009) M. Kozloff et al. ONCOLOGIST
- Radiological assessment of tumour response to anti-cancer drugs: Time to reappraise
- (2008) Peter Nygren et al. ACTA ONCOLOGICA
- Significant improvement in survival of patients presenting with metastatic colon cancer in the south of The Netherlands from 1990 to 2004
- (2008) H. J. Meulenbeld et al. ANNALS OF ONCOLOGY
- A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer
- (2008) B. Glimelius et al. ANNALS OF ONCOLOGY
- Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective
- (2008) C. McCabe et al. ANNALS OF ONCOLOGY
- Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study
- (2008) M. L. Rothenberg et al. ANNALS OF ONCOLOGY
- Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer
- (2008) D. Cunningham et al. ANNALS OF ONCOLOGY
- Treatment of the elderly colorectal cancer patient: SIOG expert recommendations
- (2008) D. Papamichael et al. ANNALS OF ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Efficacy of Oxaliplatin Plus Capecitabine or Infusional Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Randomized Trials
- (2008) Hendrik-Tobias Arkenau et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Chemotherapy After Potentially Curative Resection of Metastases From Colorectal Cancer: A Pooled Analysis of Two Randomized Trials
- (2008) Emmanuel Mitry et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
- (2008) Leonard B. Saltz et al. JOURNAL OF CLINICAL ONCOLOGY
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of Bevacizumab to Fluorouracil-Based First-Line Treatment of Metastatic Colorectal Cancer: Pooled Analysis of Cohorts of Older Patients From Two Randomized Clinical Trials
- (2008) Fairooz F. Kabbinavar et al. JOURNAL OF CLINICAL ONCOLOGY
- A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
- (2008) J. Randolph Hecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
- (2008) Carsten Bokemeyer et al. JOURNAL OF CLINICAL ONCOLOGY
- Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
- (2008) Bernard Nordlinger et al. LANCET
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started